Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
- PMID: 15551331
- DOI: 10.1002/mds.20324
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
Abstract
One-third of the 149 people recruited 15 to 18 years ago in the Sydney Multicenter Study of Parkinson's disease have survived. The original study compared low-dose levodopa with low-dose bromocriptine. We now report the problems experienced by people who survive 15 years from diagnosis. The standardized mortality ratio is significantly elevated at 1.86 and is not significantly different between treatment arms. Falls occur in 81% of patients, and 23% sustained fractures. Cognitive decline is present in 84%, and 48% fulfill the criteria for dementia. Hallucinations and depression are experienced by 50%. Choking has occurred in 50%, symptomatic postural hypotension in 35%, and urinary incontinence in 41%. No patient is still employed, and 40% of patients live in aged care facilities. Although approximately 95% have experienced L-dopa-induced dyskinesia/dystonia and end of dose failure of medication, in the majority, these symptoms are not disabling. Dyskinesia and dystonia were delayed by early use of bromocriptine, but end-of-dose failure appeared at a similar time once L-dopa was added. The rate of disease progression is similar in both arms of the study. We conclude that the most disabling long-term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L-dopa. Neuroprotective interventions in Parkinson's disease should be judged by their ability to improve non-L-dopa-responsive aspects of the disease, rather than just by their capacity to delay the introduction of L-dopa or reduce its associated side effects.
Copyright 2004 Movement Disorder Society.
Similar articles
-
Levodopa in the early treatment of Parkinson's disease.Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S17-20. doi: 10.1016/S1353-8020(09)70006-9. Parkinsonism Relat Disord. 2009. PMID: 19131036 Review.
-
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.Mov Disord. 2008 Apr 30;23(6):837-44. doi: 10.1002/mds.21956. Mov Disord. 2008. PMID: 18307261
-
Treatment of Parkinson's disease: levodopa as the first choice.J Neurol. 2002 Sep;249 Suppl 2:II19-24. doi: 10.1007/s00415-002-1204-4. J Neurol. 2002. PMID: 12375059 Review.
-
Parkinson's disease: progression and mortality in the L-DOPA era.Adv Neurol. 1996;69:3-11. Adv Neurol. 1996. PMID: 8615142 Clinical Trial. No abstract available.
-
A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.Can J Neurol Sci. 1987 Nov;14(4):576-80. Can J Neurol Sci. 1987. PMID: 3319120 Clinical Trial.
Cited by
-
Neuroinflammation and Dyskinesia: A Possible Causative Relationship?Brain Sci. 2024 May 20;14(5):514. doi: 10.3390/brainsci14050514. Brain Sci. 2024. PMID: 38790492 Free PMC article. Review.
-
Neurocognitive Impairment and Social Cognition in Parkinson's Disease Patients.Neurol Int. 2024 Apr 16;16(2):432-449. doi: 10.3390/neurolint16020032. Neurol Int. 2024. PMID: 38668129 Free PMC article. Review.
-
Therapeutic singing-induced swallowing exercise for dysphagia in advanced-stage Parkinson's disease.Front Neurol. 2024 Apr 2;15:1323703. doi: 10.3389/fneur.2024.1323703. eCollection 2024. Front Neurol. 2024. PMID: 38628693 Free PMC article.
-
Predicting Depression in Parkinson's Disease Using Commonly Available PD Questionnaires.J Clin Med. 2024 Apr 3;13(7):2069. doi: 10.3390/jcm13072069. J Clin Med. 2024. PMID: 38610834 Free PMC article.
-
[3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain.Exp Brain Res. 2024 May;242(5):1203-1214. doi: 10.1007/s00221-024-06815-w. Epub 2024 Mar 25. Exp Brain Res. 2024. PMID: 38526743 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical